• Calliditas virtual R&D Day on
    January 20, 2021

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Behind the Mystery: IgA Nephropathy

The Balancing Act, Lifetime TV’s morning program, aired a half-hour segment on IgA Nephropathy in the ‘Behind the Mystery’ program. An IgA patient and Leicester University’s Professor Jonathan Barratt discussed the disease and the challenges patients face due to lack of specifically developed treatments.

Share price Sweden

Share price US

Year-end report 2020

On February 18, 2021, at 07:00 CET, Calliditas Therapeutics published its year-end report for 2020.